Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

35 results about "Poliomyelitis Infections" patented technology

Jump to navigation Jump to search. Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the poliovirus. In about 0.5 percent of cases there is muscle weakness resulting in an inability to move.

Sabin strain poliomyelitis type I virus monoclonal antibody and application thereof

ActiveCN104357400AHigh titer reactivityGood virus specificityMicroorganism based processesImmunoglobulins against virusesEnterovirusCell strain
The invention provides a Sabin strain poliomyelitis type I virus monoclonal antibody and application thereof, and belongs to the field of immunology. The preparation method of the Sabin strain poliomyelitis type I virus monoclonal antibody comprises the following steps: carrying out immunization on mice with the Sabin strain poliomyelitis type I virus, mixing the mouse spleen cells with the mouse myeloma cells, screening and generating specific monoclonal antibody hybridoma cell strain resistaing against the Sabin strain poliomyelitis type I virus, and preserving the hybridoma cell strain with a preservation No. of CGMCC No.9231. The monoclonal antibody secreted by the hybridoma cell strain is high in valence, and has a large application prospect in diagnosis and treatment of poliomyelitis type I virus; meanwhile, the antibody can be used for specifically distinguishing poliomyelitis virus type I, type II and type III as well as other multiple enteroviruses to achieve good specificity; the Sabin strain poliomyelitis type I virus monoclonal antibody can be used for preparing an antigen content check kit for the poliomyelitis type I virus, and further used for identification and testing of the poliomyelitis type I virus, so that the Sabin strain poliomyelitis type I virus monoclonal antibody is wide in application prospect.
Owner:SINOVAC BIOTECH

Traditional Chinese medicine for treating poliomyelitis due to liver-kidney deficiency

The invention discloses traditional Chinese medicine for treating poliomyelitis due to liver-kidney deficiency. The traditional Chinese medicine is characterized by being prepared from, by weight, 5 parts of Fructus lycii, 6 parts of Fructus ligustri lucidi, 9 parts of eclipta, 9 parts of pecan kernel, 6 parts of Orobanche yunnanensis, 5 parts of Fructus rubi, 6 parts of Phacellanthus tubiflorus, 6 parts of largeleaf dogwood bark, 9 parts of Polygonum chinense root, 9 parts of Caulis akebiae root, 6 parts of Fructus corni, 3 parts of Indo-Chinese rat snake, 6 parts of Fructus acanthopanacis, 6 parts of Morinda officinalis, 10 parts of Euonymus dielsianus, 15 parts of Flemingia philippinensis, 6 parts of garden balsam root, 10 parts of Briggsia fritschii, 10 parts of Ganltheria forrestii diels, 10 parts of Caryota ochlandra root and 4 parts of licorice root. Herbs in a formulation can cooperate with each other and generate synergistic effect and can jointly play a role in tonifying liver and kidney, strengthening tendons and bones and activating blood, and the traditional Chinese medicine can effectively treat poliomyelitis due to liver-kidney deficiency; using of the traditional Chinese medicine in many patients for several years shows that effective rate reaches 96.6%.
Owner:苏吉永

Bone bi-disease Lingxianwan (pills for treating bone bi-disease)

According to the embodiment, the invention discloses a bone bi-disease Lingxianwan (pills for treating bone bi-disease). The Lingxianwan consists of herba epimedii, rhizoma curcumae longae, frankincense, myrrh, radix paeoniae alba, rhizoma corydalis, radix notoginseng, rhizoma dioscoreae nipponicae, radix aucklandiae, flos carthami, radix curcumae, radix angelicae pubescentis, radix achyranthis bidentatae, radix gentianae macrophyllae, cassia twig, dragon's blood, semen strychni. According to the embodiment, the bone bi-disease Lingxianwan provided by the invention has the following effects: 1, dredging collateral and relieving pain: the Lingxianwan can be used for treating rheumatoid arthritis or contracture and numbness; 2, relieving swelling and eliminating stagnation: the Lingxianwan can be used for treating stasis, swelling and pain caused by trauma as well as swelling and pain caused by ulcer; and the Lingxianwan has a certain curative effect on various cancers; 3, the Lingxianwan is effective on treating sequela of poliomyelitis, protrusion of lumbar intervertebral disc, prosopalgia, rheumatoid arthritis, traumatic injury, blood stasis and pain, wind-cold-wetness type of arthralgia, joint contracture and numbness in whole body, cancer swelling and the like. The Lingxianwan is mainly used for treating throat bi-pain, ulcer swelling and toxin, wandering arthritis and pain,fracture, facial paralysis and myasthenia gravis.
Owner:宁夏伊康回族医药研究所(有限公司)

Medicine for treating poliomyelitis

The invention provides a medicine for treating poliomyelitis, belonging to the technical field of medicines, and aiming at treating poliomyelitis. The medicine is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 15 parts of radix clematidis, 12 parts of peach kernels, 13 parts of ramulus uncariae cum uncis, 6 parts of apricot kernels, 12 parts of honeysuckle flowers, 10 parts of radix remanniae, 10 parts of radix achyranthis bidentatae, 10 parts of silkworm excrement, 12 parts of poria cocos, 10 parts of rhizoma gastrodiae, 10 parts of radix astragali, 10 parts of radix angelica sinensis, 10 parts of radix ginseng, 10 parts of cortex phellodendri, 10 parts of rhizoma cibotii, 10 parts of semen cuscutae, 6 parts of flos carthami, 9 parts of earthworms, and 7 parts of licorice root. For the medicine for treating poliomyelitis, poliomyelitis is analyzed from the aspect of traditional Chinese medicine, at the early stage, poliomyelitis is caused by exogenous wind, damp and heat, at the later stage, the liver and the kidney are involved, consequently, quadriplegia is caused, the main causes of poliomyelitis are middle qi deficiency, wind-damp invasion, and phlegm accumulation and blood stasis, and in the aspect of treatment, the medicines with the efficacies of dispelling the wind and activating collaterals, clearing away heat and toxic materials, tonifying the liver and the kidney, and promoting blood circulation to remove blood stasis are mixed for treatment, and the effects are obvious.
Owner:防城港市奥氏蓝科技有限公司

A kind of sabin strain poliomyelitis type I virus monoclonal antibody and its application

ActiveCN104357400BHigh titer reactivityGood virus specificityMicroorganism based processesImmunoglobulins against virusesEnterovirusMyeloma cell
The invention provides a Sabin strain poliomyelitis type I virus monoclonal antibody and application thereof, and belongs to the field of immunology. The preparation method of the Sabin strain poliomyelitis type I virus monoclonal antibody comprises the following steps: carrying out immunization on mice with the Sabin strain poliomyelitis type I virus, mixing the mouse spleen cells with the mouse myeloma cells, screening and generating specific monoclonal antibody hybridoma cell strain resistaing against the Sabin strain poliomyelitis type I virus, and preserving the hybridoma cell strain with a preservation No. of CGMCC No.9231. The monoclonal antibody secreted by the hybridoma cell strain is high in valence, and has a large application prospect in diagnosis and treatment of poliomyelitis type I virus; meanwhile, the antibody can be used for specifically distinguishing poliomyelitis virus type I, type II and type III as well as other multiple enteroviruses to achieve good specificity; the Sabin strain poliomyelitis type I virus monoclonal antibody can be used for preparing an antigen content check kit for the poliomyelitis type I virus, and further used for identification and testing of the poliomyelitis type I virus, so that the Sabin strain poliomyelitis type I virus monoclonal antibody is wide in application prospect.
Owner:SINOVAC BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products